Stockscreener 앱 받기
26.72
5.49%
1.39
시간 외 거래:
26.72
전일 마감가:
$25.33
열려 있는:
$25.4
하루 거래량:
771.61K
Relative Volume:
1.16
시가총액:
$1.97B
수익:
$81.26M
순이익/손실:
$-102.66M
주가수익비율:
-19.54
EPS:
-1.3678
순현금흐름:
$-77.62M
1주 성능:
+2.22%
1개월 성능:
+11.15%
6개월 성능:
+7.53%
1년 성능:
+104.28%
1일 변동 폭
$25.31
$26.83
1주일 범위
$24.70
$26.83
52주 변동 폭
$11.51
$29.75
Zymeworks Inc. Stock (ZYME) Company Profile
명칭
Zymeworks Inc.
전화
604-678-1388
주소
1385 West 8th Avenue, Suite 540, Vancouver, BC
Compare ZYME vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ZYME
Zymeworks Inc.
|
26.72 | 1.86B | 81.26M | -102.66M | -77.62M | -1.3678 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.94 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.59 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Zymeworks Inc. Stock (ZYME) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-12 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2025-12-03 | 개시 | Citizens JMP | Mkt Outperform |
| 2025-10-24 | 재개 | Wells Fargo | Equal Weight |
| 2025-10-14 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2025-10-10 | 개시 | B. Riley Securities | Buy |
| 2025-05-20 | 개시 | TD Cowen | Buy |
| 2024-12-16 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2024-11-07 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-11-01 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-03-21 | 재개 | Wells Fargo | Overweight |
| 2023-01-04 | 재확인 | H.C. Wainwright | Neutral |
| 2022-12-20 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-11-01 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2022-10-21 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2022-10-04 | 재개 | Wells Fargo | Overweight |
| 2022-05-05 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-03-15 | 개시 | Evercore ISI | Outperform |
| 2021-12-10 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2021-11-17 | 재개 | Guggenheim | Neutral |
| 2021-10-07 | 개시 | Jefferies | Hold |
| 2021-03-31 | 개시 | Credit Suisse | Outperform |
| 2021-02-25 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2021-02-08 | 재개 | H.C. Wainwright | Buy |
| 2021-01-25 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-09-29 | 재개 | JP Morgan | Neutral |
| 2020-08-06 | 개시 | SVB Leerink | Outperform |
| 2020-01-10 | 개시 | Wolfe Research | Outperform |
| 2019-12-09 | 개시 | JP Morgan | Neutral |
| 2019-11-25 | 개시 | H.C. Wainwright | Buy |
| 2019-11-20 | 개시 | Guggenheim | Buy |
| 2019-09-30 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2019-08-30 | 개시 | Stifel | Buy |
| 2019-07-18 | 개시 | Deutsche Bank | Buy |
| 2018-05-11 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2018-03-19 | 개시 | Raymond James | Outperform |
모두보기
Zymeworks Inc. 주식(ZYME)의 최신 뉴스
Zymeworks Inc outlines its biotech strategy as investors track clinical progress - AD HOC NEWS
Form 4 Zymeworks Inc For: 6 July By Investing.com - Investing.com Canada
Zymeworks (ZYME) COO acquires 939 ESPP shares at discounted $22.22 - Stock Titan
Price to book forward of Zymeworks Inc. – NASDAQ:ZYME - TradingView
Zymeworks' $929 Million Pivot: How a COPD Acquisition Redefines Its Future - Kavout | AI
Zymeworks Q1 2026 presentation: zanidatamab nears FDA decision - Investing.com
Zymeworks Inc outlines its antibody-drug conjugate strategy as investors watch oncology partnerships - AD HOC NEWS
Here’s Why Zymeworks Inc. Paid $929M For Theravance Biopharma (NASDAQ:ZYME) - Seeking Alpha
Zymeworks (ZYME) Stock Looks Fully Valued Despite Its 205% Three Year Run - Yahoo Finance
Arthur Cox advises Theravance Biopharma on its $929 million merger with Zymeworks - Arthur Cox LLP
Enterprise value to revenue forward of Zymeworks Inc. – BOATS:ZYME - TradingView
The Zymeworks ZW25 bispecific antibodya flexible HER2 therapy option for oncology partners - AD HOC NEWS
Canadian Zymeworks acquires American Theravance Biopharma for $929 million - AKM.RU
Is Zymeworks Inc. (ZYME) Stock an Undervalued Biotech Opportunity With Oncology Growth Ahead? - Insider Monkey
After a three-decade legacy, Theravance agreed to a complex sale for less than $1 billion - The Business Journals
Zymeworks Inc. (ZYME) M&A CallSlideshow (NASDAQ:ZYME) 2026-06-30 - Seeking Alpha
Theravance Stock Down 3% After Zymeworks Announces Buyout - Yahoo Finance
Press Release: Zymeworks to Acquire Theravance Biopharma, Inc. - Moomoo
Zymeworks agrees to buy Theravance Biopharma for $929m - Pharmaceutical Technology
Vancouver biotech Zymeworks buying Theravance for US$929M - Castanet
Zymeworks Inc to Acquire Theravance Biopharma Inc Transcript - GuruFocus
Zymeworks Inc. Stock 12‑Month Price Target Raised to $38.75, Implies 60% Upside - TradingView
Zymeworks offers US$929-million for COPD drug maker Theravance - The Globe and Mail
BTIG downgrades Theravance Biopharma stock rating on Zymeworks deal - Investing.com UK
BTIG downgrades Theravance Biopharma stock rating on Zymeworks deal By Investing.com - Investing.com South Africa
Zymeworks Buys Theravance To Execute On New Business Strategy - insights.citeline.com
Theravance, after clinical setbacks, agrees to $929M buyout - BioPharma Dive
Zymeworks bolsters royalty stream with Theravance buy - BioWorld News
B. Riley reiterates buy on Zymeworks stock after Theravance acquisition - Investing.com
Zymeworks to Acquire Theravance Biopharma, Inc. - wahanariau.com
B. Riley reiterates buy on Zymeworks stock after Theravance acquisition By Investing.com - Investing.com India
Pharma M&A Roundup: Ipsen to Acquire Kartos Therapeutics, Zymeworks to Acquire Theravance Biopharma - Pharmaceutical Executive
Zymeworks to Acquire Theravance for $929 Million, But Discounted Price Triggers Shareholder Investigation - finance.biggo.com
Stifel reiterates Zymeworks stock Buy rating at $47 target By Investing.com - Investing.com South Africa
Zymeworks expands beyond cancer with $929 million Theravance acquisition - Reuters
Zymeworks Targets Long-Term Cash Generation Through Theravance AcquisitionTheravance Biopharma (NASDAQ - Benzinga
Theravance Biopharma to Be Acquired by Zymeworks for $929 Million Plus Contingent Value Rights - Minichart
Zymeworks To Buy Theravance Biopharma In $929M Deal – A Look At What This Deal Means For TBPH Shareholders - TradingView
Stifel reiterates Zymeworks stock Buy rating at $47 target - Investing.com
Zymeworks (ZYME) to Acquire Theravance Biopharma (TBPH) for $929M in All-Cash Transaction - Blockonomi
Zymeworks to Acquire Theravance in Strategic Merger - TipRanks
Zymeworks to Buy Theravance for $17 Per Share Plus CVR - TradingView
Zymeworks (NASDAQ: ZYME) buys Theravance, adds YUPELRI cash flows with $350M OMERS note - Stock Titan
Zymeworks to acquire Theravance Biopharma for $929 million - Investing.com
Zymeworks to acquire Theravance Biopharma for $929 million By Investing.com - Investing.com Nigeria
Zymeworks to acquire Theravance Biopharma (NASDAQ: TBPH) in $929M cash and CVR deal - Stock Titan
Zymeworks Strikes $929 Million Deal for Theravance - Bloomberg.com
Zymeworks Inc.(NasdaqGS: ZYME) dropped from Russell 3000E Index - marketscreener.com
Zymeworks Inc.(NasdaqGS: ZYME) dropped from Russell Microcap Index - marketscreener.com
Zymeworks Inc.(NasdaqGS: ZYME) dropped from Russell 3000E Growth Benchmark - marketscreener.com
Zymeworks Inc.(NasdaqGS:ZYME) dropped from Russell Microcap Growth Benchmark Index - marketscreener.com
Zymeworks Inc. (ZYME) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.17%
2.48%
자본화:
|
볼륨(24시간):